The Current Ratio as of December 2025 (TTM) for Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) is 3.15

According to Infant Bacterial Therapeutics AB (publ)’s latest financial reports and current stock price. The company's current Current Ratio is 3.15. This represents a change of -5.01% compared to the average of 3.32 of the last 4 quarters.

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) Historical Current Ratio (quarterly & annually)

How has IBT-B.ST Current Ratio performed in the past?

The mean historical Current Ratio of Infant Bacterial Therapeutics AB (publ) over the last ten years is 30.16. The current 3.15 Current Ratio has changed 945.64% with respect to the historical average. Over the past ten years (40 quarters), IBT-B.ST's Current Ratio was at its highest in in the March 2019 quarter at 109.37. The Current Ratio was at its lowest in in the March 2016 quarter at 0.

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Infant Bacterial Therapeutics AB (publ) Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) Average Current Ratio

How has IBT-B.ST Current Ratio performed in the past?

The current Current Ratio of Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) Current Ratio vs. Peers

How is IBT-B.ST’s Current Ratio compared to its peers?

Infant Bacterial Therapeutics AB (publ)’s Current Ratio is less than Xspray Pharma AB (publ) (6.72), less than Cantargia AB (publ) (5.82), less than Oncopeptides AB (publ) (3.42), less than Senzime AB (publ) (5.43), less than SynAct Pharma AB (3.28), less than I-Tech AB (7.67), greater than Corline Biomedical AB (1.52), less than Guard Therapeutics International AB (publ) (4.87), greater than ADDvise Group AB (publ) (0.93), greater than Xintela AB (publ) (0.23),

Build a custom stock screener for Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Infant Bacterial Therapeutics AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Infant Bacterial Therapeutics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.